CompletedNot Applicable

Methemoglobinemia Following Intravenous Iron Treatment

Sweden50 participantsStarted 2024-09-02

Plain-language summary

Methemoglobinemia as a side effect of treatment with intravenous iron has not previously been described. This study aims to assess methemoglobin levels in patients with anemia following treatment with intravenous iron, administered as ferric carboxymaltose or ferric derisomaltose.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: for patients in the cohort study: * anemia * prescription of administration of intravenous iron (ferric carboxymaltose or ferric derisomaltose) for patients in the case report: \- patients with severe anemia who developed methemoglobinemia following administration of ferric derisomaltose Exclusion Criteria: * declined consent * known or suspected methemoglobinemia of genetic or other origin * previous administration of intravenous iron within one week before study sampling.

What they're measuring

Difference in methemoglobin after ferric derisomaltose

Timeframe: 30-120 minutes after start of iron administration

Difference in methemoglobin after ferric carboxymaltose

Timeframe: 30-120 minutes after start of iron administration

Trial details

NCT IDNCT06309641

SponsorClaudia Seiler

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-10-13

View on ClinicalTrials.gov More Methemoglobinemia trials